DIRS.INFO The most relevant business & tech news

☆ Here are Tuesday's biggest analyst calls: Apple, Nvidia, Amazon, Tesla, Seagate, Boston Beer, Planet Fitness & more
▼ + stars: | 2024-05-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Wells Fargo reiterates Nvidia as overweight Wells increased its price target on Nvidia to $1,150 per share from $970. Jefferies upgrades Boston Beer to buy from hold Jefferies said in its upgrade of the beverage company that it sees "multiple expansion." Bank of America reiterates Apple as buy Bank of America said it's sticking with its buy rating on shares of Apple. JPMorgan upgrades Planet Fitness to overweight from neutral JPMorgan said in its has increased confidence in Planet Fitness' growth. JPMorgan upgrades Vtex to overweight from neutral JPMorgan said it sees an attractive entry point for the software-as-a-service company.

Persons: Tesla, Goldman Sachs, Goldman, it's, Wells, ests, Jefferies, Beer, Roth, Morgan Stanley, GXO's, Baird, Oppenheimer, Edwards Organizations: Barclays, Oncology, Fulcrum Therapeutics, ISI, Nvidia, Jefferies, Boston Beer, GXO Logistics, Bank of America, Apple, HSBC, Citi, Weatherford, Energy, JPMorgan, LT, Fortrea Holdings, Edison International, RBC, North, Deutsche Bank, Amazon, Deutsche, Western Digital, Seagate Locations: China, North America

☆ US food insecurity: The rising cost of living makes it hard for people with jobs to feed their families
▼ + stars: | 2024-05-04 | by ( Tami Luhby | ) edition.cnn.com time to read: +6 min

CNN —The mix of local residents visiting the Enfield Food Shelf in Connecticut has changed a lot in the last few years. It now seems that one unexpected expense tips people’s finances.”Between 300 and 400 households visit the Enfield Food Shelf in Connecticut each week. Khamphay Khen shops at the Enfield Food Shelf to help feed his family of six. The Enfield Food Shelf serves between 300 and 400 households a week. “Even though there are a lot of jobs available, and the unemployment rate is low, we’re seeing food insecurity increasing,” said East.

Persons: Kathleen Souvigney, Souvigney, ”, “, Jason Jakubowski, Khamphay, he’s, Khen, Honda, it’s, Enfield, Chloe East Organizations: CNN, Enfield Food, Survey, Connecticut Foodshare, Enfield Food Shelf, Urban Institute, The Hamilton, Brookings Institution Locations: Connecticut, Enfield, America

☆ This rare muscle disease play can rally more than 50%, BofA says
▼ + stars: | 2024-05-03 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Avidity Biosciences stock has more room to run thanks to the company's pipeline of multiple treatments for rare muscle disorders, according to Bank of America. Avidity has a therapeutic platform — antibody oligonucleotide conjugates — that was well-received at the time it went public in 2020, Meacham said. But shares were hurt by a clinical hold on Avidity's leading program for treating an uncommon muscle disorder, DM1. The program, tested in the Marina trial, recently saw long-term data that has "helped lift that key overhang on the stock," Meacham said. Those catalysts are tied to two other drugs in the muscle disorder space that are expected to report data this year, according to Meacham.

Persons: Geoff Meacham, Meacham Organizations: Biosciences, Bank of America Locations: San Diego, Thursday's

☆ Here are Friday's biggest analyst calls: Apple, Target, Coinbase, Berkshire Hathaway, Estee Lauder & more
▼ + stars: | 2024-05-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

JPMorgan upgrades Williams-Sonoma to neutral from underweight JPMorgan said in its upgrade of the stock that the home furnishings category is stabilizing. "We are downgrading shares of EXPE to Mkt Perform from OP with a target price of $145 vs. $165 previously." JPMorgan upgrades Joby to neutral from underweight JPMorgan said its bear thesis has largely played out for the aviation company. Guggenheim reiterates Target as buy Guggenheim said investors should buy the dip in shares of Target . Morgan Stanley downgrades Estee Lauder to equal weight from overweight Morgan Stanley said it sees a slower recovery for shares of Estee Lauder .

Persons: Stifel, Wells, Truist, OLLI, Guggenheim, Tim Cook, William Blair, Amgen, Jefferies, We've, Ari sta, it's, Morgan Stanley downgrades Estee Lauder, Morgan Stanley, Estee Lauder, TD Cowen, Parsons, Bernstein, Oppenheimer, CFRA, Berkshire Hathaway Organizations: RBC, FTAI Aviation, Pacific, Union Pacific, JPMorgan, Williams, WSM, BMO, Bank of America, Apple, Kiniksa Pharmaceuticals, JOBY, Guggenheim, Target, Citi, MCW, Arista, PSN, Avidity, ~$ Locations: Sonoma, EXPE, GEICO

☆ FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
▼ + stars: | 2024-04-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The Food and Drug Administration on Friday approved Pfizer 's treatment for a rare genetic bleeding disorder, making it the company's first-ever gene therapy to win clearance in the U.S. The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements. Without that protein, called factor IX, patients with hemophilia B bruise easily and bleed more frequently and for longer periods of time. The gene therapy will compete with Australia-based CSL Behring's Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. The company is also developing a gene therapy for Duchenne muscular dystrophy, a genetic disorder that causes muscles to weaken gradually.

Persons: IX, hemophilia, Adam Cuker, Cuker Organizations: Drug Administration, Pfizer, U.S, Penn's, Spark Therapeutics, hemophilia Locations: U.S, Australia

☆ Morgan Stanley says M&A will rebound and these stocks have an 'elevated likelihood' of a takeover
▼ + stars: | 2024-03-05 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Global mergers and acquisition activity will soar this year, and several names could benefit from the comeback, according to Morgan Stanley. The firm expects global M & A volume activity to rise by 50% this year compared to 2023. "We believe that a cyclical and structural rebound in M & A is coming," Morgan Stanley said in a note titled "Stocks with Elevated Likelihood of Receiving an Offer," which was released Monday. Morgan Stanley pointed out that 2021 to 2023 could have seen a drop of activity worth between $4 trillion and $11 trillion. Morgan Stanley said it has no information about M & A activity involving the companies.

Persons: Morgan Stanley, Morgan, Stephen Ju, Morgan Stanley's Organizations: Health, Sarepta Therapeutics, Tenet Healthcare, Analysts, BMO Capital Markets, UBS, Hertz Global Holdings Locations: Europe

☆ Opinion | Three Mothers’ Plea to the F.D.A.: Save Our Children
▼ + stars: | 2024-02-28 | by ( ) www.nytimes.com time to read: +1 min

To the Editor:Re “Why Can’t More Children Get the Treatment That Saved My Son’s Life?,” by Elizabeth Currid-Halkett (Opinion guest essay, Feb. 24):Our three children, ages 5 and 7, battle a rare, relentless and ultimately fatal disease called cystinosis. We recently found hope in the initial phase of a gene therapy clinical trial that was shown to be safe and yielded very promising results — a therapy that could one day save our children’s lives. Our biggest fear is that it will not be accessible to them or others in desperate need. We applaud Dr. Marks’s wisdom and perspective. reviewers’ initial rejection is a cautionary tale of how patient access to lifesaving therapies could be impeded by a narrow interpretation of efficacy.

Persons: Elizabeth Currid, Currid, Peter Marks, “ Organizations: Biologics

☆ Gene Therapies Could Transform Rare Diseases. Are We Holding Them Back? - The New York Times
▼ + stars: | 2024-02-19 | by ( Elizabeth Currid-Halkett | ) www.nytimes.com time to read: +1 min

On Jan. 8, 2020, as I was parking my car, I got a long-awaited phone call from one of my son’s doctors. She informed me that our 7-month-old son, Eliot, had Duchenne muscular dystrophy, a fatal neuromuscular disease. I can see my neighbor walking up her steps with groceries, a leaf falling, oblivious to the devastation below. It is caused by a genetic mutation on the X chromosome, thus the disease almost exclusively affects boys (one in 3,300). lose muscle mass and thus the ability to do basic things like run and walk.

Persons: Eliot, Joan Didion, D.M.D, Jerry Mendell Organizations: Nationwide Children’s Hospital, D.M.D Locations: Columbus , Ohio

☆ Jim Cramer looks outside the Magnificent Seven, names other companies with shares that are popping
▼ + stars: | 2024-02-08 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Thursday encouraged investors to look beyond the Magnificent Seven, saying there's money to be made in other companies. Cramer named several stocks that have seen percentage gains of 10% or higher since Tuesday's close. Trucking company XPO caught Cramer's eye as its stock was able to soar thanks to a better-than-expected quarter. Cramer also named infrastructure company Advanced Drainage Systems , saying there's so much activity in the sector it's not hard to make money there. Some stocks are seeing gains thanks to innovative new tech, he added, pointing to the recent climb of Regenxbio .

Persons: CNBC's Jim Cramer, Cramer, XPO, we've Organizations: Trucking, Nvidia, Broadcom, Drainage Systems

☆ Comeback stocks: These names have jumped to start 2024 after falling last year
▼ + stars: | 2024-02-05 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

The Russell 1000 , which tracks the top 1,000 largest companies — large- and mid-cap names — is up about 3% in 2024. With this in mind, CNBC Pro screened for the stocks making a comeback in 2024. However, the consensus price target is just 4.6% from its current levels — putting into question whether there's more room for upside. Just 35.7% of analysts are bullish on the shares, and the average price target implies shares can grow just 4.3%. Sarepta Therapeutics has soared 27.4% this year — and it could jump 20.1% more according to its consensus price target, per LSEG.

Persons: Russell, they're, Merck's, Sarepta Organizations: CNBC Pro, Pharmaceutical, Merck, Verizon, Barclays, VZ, LSEG, Novo Nordisk, Sarepta Therapeutics Locations: Novo

☆ At Sundance, a reckoning with our digital selves
▼ + stars: | 2024-01-29 | by ( Thomas Page | ) edition.cnn.com time to read: +11 min

Harper that premiered at this month’s Sundance Film Festival, rapper Kemba enters an electronics store. Sundance is a broad church, but one throughline this year was a reckoning with our digital selves. Courtesy of Sundance InstituteIn the game Steen could be whatever he wanted to be, do whatever he wanted to do. The Sundance Film Festival concluded on January 28. Documentary Competition)“Sujo” (World Cinema Dramatic Competition)“A New Kind of Wilderness” (World Cinema Documentary Competition)Audience Favorite Awards“Daughters” (U.S.

Persons: J.M, Harper, Kemba, “, headspace Harper, Deus, J.M . Harper, Jazmin Jones, Olivia McKayla Ross, Mavis Beacon, Mandela, she’s, Jones, McKayla Ross Gen, we’re, Siri, knotty, L’espérance, feelgood, Thelma, Squibb, Beacon, Yeleen Cohen, ”, Kristin Stewart, Sam, Andy Zuchero, Stewart, Steven Yeun, Déja, Liam, “ Sebastian ”, Mikko Mäkelä, Ruaridh, Mollica, David Nellist, Sebastian, James Watson, “ Ibelin, Benjamin Ree, Mats Steen, Steen, Steen’s, Ibelin . Ibelin, he’d, Ree, Ibelin, Steen's avater Ibelin, It’s, ’ “, Steen –, Sujo, Dìdi ”, Ibelin ”, Kneecap Organizations: CNN, Sundance, Motorola, Sundance Institute, Americans, Iam, AIs, Netflix, Sundance Film Locations: “, Haiti, ”, New York, Norwegian

☆ Ohio woman charged after police say she faked her daughter's cancer diagnosis to raise thousands of dollars
▼ + stars: | 2024-01-13 | by ( Kenneth Niemeyer | ) www.businessinsider.com time to read: +3 min

Ohio authorities have accused a woman of faking her daughter's cancer diagnosis to raise money. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementAuthorities in Ohio say a woman faked her daughter's cancer diagnosis and used it to raise thousands of dollars in online fundraisers for her treatment. The sheriff's office said it received a tip that a local child was being used to improperly raise money based on the public portrayal that they had cancer. AdvertisementAuthorities said in the document that school officials noted that Reed's child has already missed more than 280 hours of school this school year.

Persons: Pamela Reed, —, Reed, isn't, Kelly Turner, Olivia, Turner, Gypsy Rose Blanchard, Dee Dee, Blanchard, Rose Blanchard, Nicholas Godejohn, Clauddine Blanchard, Godejohn Organizations: Service, Sheriff's, Law &, Reed's, Authorities, The New York Times, Times, Humanity Locations: Ohio, Noble, United States, Colorado, Habitat

☆ Fresh from a murder sentence, Gypsy Rose Blanchard is becoming the internet's favorite influencer
▼ + stars: | 2024-01-10 | by ( Lindsay Dodgson | ) www.businessinsider.com time to read: +9 min

The 32-year-old was recently released from prison after eight years for orchestrating the murder of her mother, Clauddine "Dee Dee" Blanchard. Where Gypsy Rose Blanchard's story beganDee Dee Blanchard and Gypsy Rose Blanchard. AdvertisementBehind closed doors Dee Dee was overbearing, but to the outside world, it was a different story. She was also a lot older than Dee Dee was telling people she was. In one with People after her release, she said killing Dee Dee was an act of "panic" and "desperation" because she was facing yet another surgery.

Persons: —, Rose Blanchard, Dee Dee, Blanchard, Blanchard shouldn't, Elizabeth Holmes, Nina Vargas, Dee Dee Blanchard, Gypsy Rose Blanchard, Joey King, Patricia Arquette, Dee Dee's, Nicholas Godejohn, Dee, Godejohn, I'm, Blanchard hasn't, She's, Claudia Oshry, Time's, Amanda Hirsch, notskinnybutnotfat, Ryan Anderson, Vargas, Jamie McCarthy, TikTok, Jessica Maddox, she's, Maddox Organizations: Service, Business, ABC News, Police, Getty, The University of Alabama Locations: Missouri, Dee, TikTok

☆ Biden’s Race Against a Cure
▼ + stars: | 2023-11-13 | by ( The Editorial Board | ) www.wsj.com time to read: 1 min

Wonder Land: Citing the president’s age lets Democrats off the hook for the political failure of his economic policies. Images: AP/AFP/EPA/Getty Images Composite: Mark KellyThe Food and Drug Administration may soon approve two gene therapies with the potential to cure more than 100,000 Americans with debilitating sickle-cell disease. Gene therapies fix missing or defective genes. The one-time treatments have the potential to cure inherited disorders with early death sentences. The FDA has approved nine gene therapies for such diseases as Duchenne muscular dystrophy, spinal muscular atrophy and retinal dystrophy.

Persons: Mark Kelly The Organizations: AFP, EPA, Drug Administration, Medicare, Medicaid Services, FDA

Executives of some beaten-down companies, including one battered biotech name and a popular soft drinks maker, scooped up shares of their own stock in the past week. Here are the top insider buys: Energy Transfer — Executive Chairman Kelcy Warren bought one million shares Monday at $13.53 per share for a total value of $13.53 million. Shares are up more than 2% over the past month. Enstar Group CEO bought swathes of shares Wednesday, the day after the company reported its earnings for the third quarter. The stock has gained about 8% so far this year and shares are up roughly 4% over the past month.

Persons: Kelcy Warren, Dominic F, Silvester, Nigel W, Morris, Richard Barry, Verity, Douglas Ingram, Keurig Dr Pepper, Timothy P, Cofer, Dr Pepper's, Dr Pepper —, Dr Pepper, Mott's —, Enstar Organizations: CNBC Pro, —, Global, Therapeutics, Remitly, FDA, U.S . Securities, Exchange, Enstar Locations: Canada

☆ Beware these companies due to report earnings that have negative profit momentum
▼ + stars: | 2023-11-09 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

CNBC Pro screened for the S & P 500 companies still reporting next week that analysts have expressed the most caution on — by cutting their earnings estimates ahead of the reports. Analyst consensus earnings estimates are down at least 5% over the past three months. Analyst consensus earnings estimates are down at least 5% over the past six months. CTLT YTD mountain Catalent YTD chart "Catalent (CTLT) became a very noticeable laggard in the life science space about fifteen months ago. Meat producer Tyson Foods , which is due to report earnings premarket on November 13, was also among the stocks with negative earnings momentum.

Persons: Gordon Haskett, Don Bilson, Bilson, Catalent, Michael Lasser, Lasser, Morgan Stanley, BBWI, Alex Straton, Tyson Foods, — CNBC's Michael Bloom Organizations: CNBC Pro, Biotechnology, Sarepta Therapeutics, Dystrophy, UBS, 3Q, Body Locations: Columbus , Ohio, Bath

☆ Former FDA commissioner Dr. Scott Gottlieb on the future of gene therapy
▼ + stars: | 2023-11-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFormer FDA commissioner Dr. Scott Gottlieb on the future of gene therapyFormer FDA commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the future of gene therapy, after Sarepta Therapeutics revealed new data for its Duchenne Muscular Dystrophy gene therapy fell short of expectations, the state of Covid-19, and more.

Persons: Scott Gottlieb Organizations: Former, Sarepta Therapeutics Locations: Covid

☆ Murky road ahead for Duchenne gene therapy as confirmatory trial misses main goal
▼ + stars: | 2023-10-31 | by ( Meg Tirrell | ) edition.cnn.com time to read: +4 min

Sarepta gave the one-time drug a price tag of $3.2 million, making it the second most-expensive medicine in the world. DMD affects one in 3,500 to 5,000 newborns, mostly boys because of the way it’s inherited, according to Johns Hopkins Medicine. The primary goal of the confirmatory trial was improvement on a measure known as the North Star Ambulatory Assessment, a scale of how well kids can stand, walk and perform other movements. The difference wasn’t statistically significant, meaning technically the study failed to meet its main goal. The company said no new safety issues emerged in the trial, which it called EMBARK.

Persons: Doug Ingram, ” Ingram, Sarepta, “, Dr, Sanjay Gupta, Ingram, ” Organizations: CNN, US Food and Drug Administration, Sarepta Therapeutics, FDA, Johns Hopkins Medicine, North Star, CNN Health

☆ The life and career of Lululemon founder Chip Wilson
▼ + stars: | 2023-10-27 | by ( Jordan Hart | Jennifer Ortakales Dawkins | ) www.businessinsider.com time to read: +2 min

Chip Wilson founded Lululemon Athletica Inc. in 1997 after selling his first apparel company. Wilson has lived with a rare muscular disease for over 30 years. AdvertisementAdvertisementLululemon 's billionaire founder Chip Wilson has been the center of both acclaim and controversy. He spends part of his fortune on philanthropy and researching a cure for the rare muscular disease called facioscapulohumeral muscular dystrophy, which he was diagnosed with at 32 years old. Here's everything we know about Wilson's life and career as the founder and former CEO of Lululemon.

Persons: Chip Wilson, Wilson, —, women's Organizations: Lululemon Athletica, Service, Bloomberg

☆ These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
▼ + stars: | 2023-10-22 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. "This is a major shortcoming in terms of not just quality of life for the patients who have to lose lean muscle mass, but there's actually room to improve on the weight loss and there [are] other metabolic benefits to improving your lean muscle mass ... [including] you might have better durability of weight loss." The drug is being tested in a phase 2b study alongside semaglutide to protect against loss of muscle mass. Until then, patients will need to watch what they eat and focus on exercise just as they would on any other weight loss regimen. When that occurs, muscle loss will be an even bigger issue than it is now.

Persons: Piper Sandler, Allison Bratzel, there's, Bratzel, Versanis, Eli Lilly, Eli Lilly's Mounjaro, they're, Lydia Alexander, Alexander, Sandler's Bratzel, incretins, Biohaven, Nestle, Ulf Mark Schneider, Jeff Jonas, Jonas, Stephens, Jim Salera, Atkins, Morgan Stanley, — CNBC's Michael Bloom Organizations: Wall, Nordisk's Ozempic, Obesity Medicine Association, Bristol Myers Squibb, Nestle, Gabelli, Quest, Foods Locations: Swiss

☆ The founder of Lululemon is spending $100 million to try to beat the super rare disease that's destroying his muscles
▼ + stars: | 2023-10-22 | by ( Lakshmi Varanasi | ) www.businessinsider.com time to read: +3 min

Lululemon founder Chip Wilson is battling FSHD, a rare form of muscular dystrophy. He's investing $100 million into finding a cure through his venture philanthropy fund, Solve FSHD. AdvertisementAdvertisementLululemon founder Chip Wilson has been battling a rare muscular disease for the past several decades, and he's funneling $100 million of his multibillion net worth into finding a cure. Wilson suffers from an even more uncommon form called FSHD2 that impacts just 5% of those with the disease, Bloomberg noted. Solve FSHD did not immediately respond to Insider's request for a comment.

Persons: Chip Wilson, FSHD, He's, Wilson Organizations: Morning, Bloomberg, FSHD Society, China's, Anta, Products, Amer Sports

☆ A disabled Israeli teenager with muscular dystrophy is a hostage held by Hamas in Gaza after she was abducted from the Supernova music festival
▼ + stars: | 2023-10-14 | by ( Rebecca Rommen | ) www.businessinsider.com time to read: +3 min

Hamas militants took a disabled 17-year-old hostage who attended the Supernova music festival. AdvertisementAdvertisementA disabled 17-year-old girl, Rut Perez, is among the 150 hostages abducted by Hamas militants, The Times of London reports. The vulnerable teenager, who has muscular dystrophy, was attending the Supernova festival near the Gaza border when Hamas militants massacred over 260 attendees. Rut attended the electronic music festival with her sister, Yamit, and her father. "I want to believe there are good people in this world and they will help us get our family back," Yamit told The Times.

Persons: Perez, —, Yamit, Israel Organizations: Supernova, Service, Times, Palestinian, UN Locations: Gaza, London, Tel Aviv

☆ Stocks making the biggest moves midday: General Motors, Stellantis, Planet Fitness, Adobe and more
▼ + stars: | 2023-09-15 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

Nucor — The steelmaker fell 6.1% after offering worse-than-expected guidance for third-quarter earnings, with the company pointing to pricing and volume challenges. Core & Main — The infrastructure stock retreated 4.1% a day after it announced a secondary stock offering. The bank said Apellis has a favorable risk/reward ahead of third-quarter earnings. The Wall Street firm said the resumption of loan repayments introduce bookings risk to food delivery. The Wall Street firm said its pessimistic outlook was changing despite recent underperformance in the reinsurance space.

Persons: Stellantis, Chris Rondeau, Rondeau, Craig Benson, Nucor, Raymond James, Needham, Charles Shi, Lam, Goldman Sachs, Apellis, MoffettNathanson, Estée Lauder, Goldman, Yun Li, Jesse Pound, Samantha Subin, Pia Singh, Brian Evans, Lisa Kailai Han Organizations: UAW, General Motors Wentzville, General Motors, Ford, United Auto Workers began, Workers, CNBC, LSEG, PTC Therapeutics, Medicines Agency's, Medicinal Products, Arm, Investment, Bloomberg News, Apple, Dexcom, ASML Holding, Lam Research, Taiwan Semiconductor, Adobe, Bank of America, JPMorgan, Apellis Pharmaceuticals, Waste Systems Locations: Wentzville , Missouri, New Hampshire, Wells, underperform

☆ Analysts love these Nasdaq stocks as benchmark wraps up best first half since 1983
▼ + stars: | 2023-06-27 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

The tech-heavy index has soared nearly 29% this year and is currently on pace for its best first half since 1983. That year, the Nasdaq rallied 37.1% in the first half and finished 1983 up nearly 20%. Their average price target implies about 34% upside compared with current levels. Three-quarters of analysts covering the stock rate it a buy, and the average price target indicates 30% upside over the next 12 months. Of the 14 analysts covering the stock, 71% rate it a buy, while the average analyst price target implies upside of nearly 64%.

Persons: Ambrx, FANG, Canaccord Genuity Organizations: Nasdaq, Apple, Google, Nvidia, CNBC Pro, Diamondback Energy, Mobileye, Sarepta Therapeutics, U.S . Food, Drug Administration Locations: Texas, U.S

☆ Sarepta slumps as concerns emerge around upcoming gene therapy data
▼ + stars: | 2023-06-23 | by ( ) www.reuters.com time to read: +2 min

June 23 (Reuters) - Sarepta Therapeutics shares (SRPT.O) slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use. The U.S. health regulator had on Thursday granted Sarepta's Elevidys therapy accelerated approval to treat DMD patients aged between 4 and 5 years who can walk, contrary to the company's application for all patients who can walk. Sarepta's gene therapy is the first of its kind for DMD, an inherited progressive muscle-wasting disorder that almost always affects young boys. Elevidys, a one-time treatment, is expected to change the way that DMD patients are treated as current therapies require regular use. William Blair's Tim Lugo called the treatment "transformational for Duchenne's patients" and "a significant opportunity for Sarepta".

Persons: Sarepta's, Gavin Clark, Gartner, William Blair's Tim Lugo, Leroy Leo, Khushi, Devika Organizations: Sarepta Therapeutics, Food and Drug, BioMarin Pharmaceuticals, Thomson Locations: U.S, Bengaluru

Search resuls for: "Dystrophy"

25 mentions found